EPO Protein (AA 28-193) (His tag)

Produktnummer ABIN7505129

Produktdetails

Target: EPO (Erythropoietin (EPO))

Protein-Typ: Recombinant

Proteineigenschaft: AA 28-193

Spezies: Human

Quelle: Escherichia coli (E. coli)

Aufreinigungstag / Konjugat: Dieses EPO Protein ist gelabelt mit His tag.

Sequenz: Ala 28-Arg 193

Produktmerkmale: A DNA sequence encoding the Human EPO protein (P01588) (Ala 28-Arg 193) was expressed with a C-His tag.

Reinheit: > 95 % as determined by reducing SDS-PAGE.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween80 are added as protectants before lyophilization.

Lagerung: 4 °C,-20 °C,-80 °C

Informationen zur Lagerung: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Haltbarkeit: 12 months

Antigendetails

Target: EPO (Erythropoietin (EPO))

Andere Bezeichnung: EPO (EPO Produkte)

Synonyme: EPO Protein, EP Protein, MVCD2 Protein, erythropoietin Protein, erythropoietin S homeolog Protein, erythropoietin a Protein, EPO Protein, epo Protein, epo.S Protein, Epo Protein, epoa Protein

Substanzklasse: Hormone

Hintergrund:

Abbreviation: EPO

Target Synonym: Epoetin,EPO,Erythropoietin

Background: Erythropoietin (EPO) is a 34 kDa glycoprotein hormone in the type I cytokine family and is related to thrombopoietin. Its three N-glycosylation sites, four alpha helices, and N- to C-terminal disulfide bond are conserved across species. Glycosylation of the EPO protein is required for biological activities in vivo. The mature human EPO protein shares 75 % - 84 % amino acid sequence identity with bovine, canine, equine, feline, mouse, ovine, porcine, and rat EPO. EPO is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules. It is also produced in much lower, but functionally significant amounts by fetal hepatocytes and in adult liver and brain. EPO promotes erythrocyte formation by preventing the apoptosis of early erythroid precursors which express the erythropoietin receptor (EPO R). EPO R has also been described in brain, retina, heart, skeletal muscle, kidney, endothelial cells, and a variety of tumor cells. Ligand induced dimerization of EPO R triggers JAK2-mediated signaling pathways followed by receptor/ligand endocytosis and degradation. Rapid regulation of circulating EPO allows tight control of erythrocyte production and hemoglobin concentrations. Anemia or other causes of low tissue oxygen tension induce erythropoietin production by stabilizing the hypoxia-induceable transcription factors HIF-1 alpha and HIF-2 alpha. EPO additionally plays a tissue-protective role in ischemia by blocking apoptosis and inducing angiogenesis.

Molekulargewicht:

Calculated MW: 18.15 kDa

Observed MW: 20 kDa

UniProt: P01588

Pathways: JAK-STAT Signalweg, Hormone Activity, Negative Regulation of intrinsic apoptotic Signaling, Negative Regulation of Transporter Activity